Hospital Acute Care
Aggrastat® (tirofiban hydrochloride) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in patients with Acute Coronary Syndrome. For full prescribing information, including further details about indications, contraindications, warnings and precautions, please consult the Aggrastat Product Monograph.
Brinavess® (vernakalant hydrochloride) is for the rapid conversion of recent onset atrial fibriallation (“AF”) to sinus rhythm in adults, for non-surgery patients with AF of seven days or less and for use in post-cardiac surgery patients with AF of three days or less. Brinavess is NOT recommended for conversion of atrial flutter (AFL) to sinus rhythm.
Download Product Monograph
ENGLISH | FRENCH
Download Pre-Infusion Checklist
ENGLISH & FRENCH